Overview
Siliq (brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Coverage Guidelines
Authorization may be reviewed on a case by case basis for members new to AllWays Health Partners who are currently receiving treatment with Siliq excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

**Moderate -Severe Plaque Psoriasis**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. **ONE** of the following:
   a. Paid claims or physician documented inadequate response or adverse reaction to **ONE** conventional therapy (see appendix B)
      i. topical agent
      ii. phototherapy
      iii. systemic agent
   b. Contraindication to **ALL** conventional therapies:
      i. topical agents
Continuation of Therapy
Reauthorization requires physician documentation of continuation of therapy, positive response to therapy, FDA approved indication and appropriate dosing.

Limitations
1. Initial approvals will be granted for 3 months.
2. Reauthorizations will be granted for 12 months.
3. The following quantity limits apply:

<table>
<thead>
<tr>
<th>Product</th>
<th>Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siliq 210mg/1.5mL</td>
<td>2 syringes per 28 days</td>
</tr>
</tbody>
</table>

Appendix
Appendix A: Dosing

<table>
<thead>
<tr>
<th>Product</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siliq (brodalumab)</td>
<td>SQ: 210 mg initially at week 0, 1 and 2; followed by 210 mg every two weeks</td>
</tr>
</tbody>
</table>

Appendix B. Conventional Therapies for Plaque Psoriasis

<table>
<thead>
<tr>
<th>Conventional Treatment Lines</th>
<th>Agents Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical Agents</td>
<td>emollients, keratolytics, corticosteroids, coal tar, anthralin, calcipotriene, tazarotene, calcitriol, calcineurin inhibitors</td>
</tr>
<tr>
<td>Systemic Agents</td>
<td>Traditional DMARDs: methotrexate, apremilast, acitretin,</td>
</tr>
<tr>
<td>Phototherapy</td>
<td>ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA), narrow band UV-B (NUVB)</td>
</tr>
</tbody>
</table>

References

Review History
03/01/18 – Reviewed (adopted MH RS)
02/20/19 – Reviewed in P&T Meeting

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.